Insider Trading Activity CymaBay Therapeutics Inc. (NASDAQ:CBAY) – SVP Bought 5,000 shares of Stock

ME Staff
-
0

Insider Trading Activity For CymaBay Therapeutics Inc. (NASDAQ:CBAY)

Charles Mcwherter , SVP of CymaBay Therapeutics Inc. (NASDAQ:CBAY) reportedly Bought 5,000 shares of the company’s stock at an average price of 7.43 for a total transaction amount of $37,150.00 SEC Form

Insider Trading History For CymaBay Therapeutics Inc. (NASDAQ:CBAY)

  • On 5/15/2015 Charles Mcwherter, VP, bought 2,000 with an average share price of $3.16 per share and the total transaction amounting to $6,320.00.View SEC Filing
  • On 5/18/2015 Wart Harold Van, CEO, bought 7,500 with an average share price of $3.34 per share and the total transaction amounting to $25,050.00.View SEC Filing
  • On 5/18/2015 Sujal Shah, CFO, bought 10,000 with an average share price of $3.40 per share and the total transaction amounting to $34,000.00.View SEC Filing
  • On 7/20/2015 Emster Kurt Von, Director, bought 1,600,000 with an average share price of $2.81 per share and the total transaction amounting to $4,496,000.00.View SEC Filing
  • On 8/14/2015 Emster Kurt Von, Director, bought 90,000 with an average share price of $2.69 per share and the total transaction amounting to $242,100.00.View SEC Filing
  • On 9/11/2015 Carl Goldfischer, Director, sold 46,729 with an average share price of $2.74 per share and the total transaction amounting to $128,037.46.View SEC Filing
  • On 4/4/2016 Sujal Shah, CFO, bought 22,000 with an average share price of $1.39 per share and the total transaction amounting to $30,580.00.View SEC Filing

    • Analyst Ratings For CymaBay Therapeutics Inc. (NASDAQ:CBAY)
    These are 5 Buy Ratings, 1 Strong Buy Rating .
    The current consensus rating for CymaBay Therapeutics Inc. (NASDAQ:CBAY) is Buy (Score: 3.17) with a consensus target price of $12.80 , a potential (65.16% upside)

    Analyst Ratings History For CymaBay Therapeutics Inc. (NASDAQ:CBAY)

    • On 7/1/2016 Roth Capital Initiated Coverage of rating Buy
    • On 7/17/2017 HC Wainwright Boost Price Target of rating Buy with a price target of $7.00 to $12.00
    • On 7/17/2017 Piper Jaffray Companies Set Price Target of rating Buy with a price target of $7.00
    • On 7/17/2017 Ifs Securities Reiterated Rating Strong-Buy
    • On 7/20/2017 Citigroup Inc. Reiterated Rating Outperform with a price target of $8.00 to $15.00
    • On 7/20/2017 Oppenheimer Holdings, Inc. Boost Price Target of rating Outperform with a price target of $8.00 to $15.00
    • On 7/20/2017 CIBC Reiterated Rating Outperform to Outperform with a price target of $8.00 to $15.00

    Recent Trading Activity for CymaBay Therapeutics Inc. (NASDAQ:CBAY)
    Shares of CymaBay Therapeutics Inc. closed the previous trading session at 7.75 up +0.45 6.16% with 2,637,836 shares trading hands.